110
Participants
Start Date
October 17, 2024
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2027
Disitamab Vedotin
2.5 mg/kg IV every 3 weeks
Sintilimab
200 mg IV every 3 weeks
S-1
40-60 mg BID for 14 days, every 3 weeks
Trastuzumab
First load dose is 8.0mg/kg , then 6.0 mg/kg IV every 3 weeks
Oxaliplatin
130 mg/m2 Q3W
Capecitabine
1000 mg/m² Q3W
5-FU
800 mg/m²
Cisplatin
80 mg/m²
RECRUITING
Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan
RECRUITING
Shandong Provincial Third Hospital, Jinan
RECRUITING
Shandong Univerisity Qilu Hospital, Jinan
RECRUITING
Qilu Hospital of Shandong University(Qingdao), Qingdao
RECRUITING
Tengzhou Central People's Hospital, Tengzhou
RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
NOT_YET_RECRUITING
Binzhou Medical University Hospital, Binzhou
RECRUITING
Shengli Oilfield Central Hospital, Dongying
RECRUITING
Jinan Third People's Hospital, Jinan
RECRUITING
Affiliated Hospital of Jining Medical College, Jining
RECRUITING
Liaocheng People's Hospital, Liaocheng
RECRUITING
Linyi Cancer Hospital, Linyi
NOT_YET_RECRUITING
The Affiliated Hospital of Qingdao University, Qingdao
NOT_YET_RECRUITING
Taian City Central Hospital, Taian
RECRUITING
The Second Affiliated Hospital of Shandong First Medical University, Taian
NOT_YET_RECRUITING
Weifang Hospital of Traditional Chinese Medicine, Weifang
RECRUITING
Yantai Yuhuangding Hospital, Yantai
RECRUITING
Yantaishan Hospital, Yantai
RECRUITING
Zibo Central Hospital, Zibo
RECRUITING
Zibo First People's Hospital, Zibo
Qilu Hospital of Shandong University
OTHER